Global Health Ltd (MEDANTA) Q1 FY27 Earnings Call: Plans Rs.4,850 Cr Capex for 2,950 Beds, Guides Earlier Noida EBITDA Breakeven

Global Health Ltd held its Q1 FY27 earnings call on July 30, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Financials & Key Metrics

• Consolidated income Rs.13,262 Mn — up 26% YoY in Q1 FY 2026-2027, driven by broad-based patient volume growth across the network.
• EBITDA Rs.3,153 Mn (23.8% margin) — excl. Noida, EBITDA was Rs.3,201 Mn (25.8% margin), reflecting core operating strength before the new unit's drag.
• PAT Rs.1,573 Mn — compared to Rs.1,590 Mn in Q1 FY 2025-2026, which included a non-recurring exceptional income of Rs.196 Mn (EPCG liability reversal); underlying earnings trend is healthy.
• IP volumes +28% YoY — OP volumes +34% YoY, occupied bed days +21% YoY; network occupancy at 63% (excl. Noida: 66%).
• ARPOB Rs.70,244 (+5% YoY) — ARPP (avg. revenue per patient) at Rs.2,01,891, broadly stable YoY; total operational bed capacity reached 7,337 (net +72 beds in Q1).

Margin Dynamics & Growth Drivers

• Cluster 1 (Gurgaon, Indore, Ranchi) revenue Rs.7,715 Mn — up 10% YoY in Q1 FY 2026-2027, with EBITDA margin expanding to 24.1% (vs. 23.4% YoY) and ARPOB +7% YoY; occupancy 63%.
• Cluster 2 (Lucknow, Patna, Noida) total income Rs.4,983 Mn — up 55% YoY; excl. Noida, revenue grew 28% and EBITDA +40% YoY, with a margin of 32%.
• Margin differences are operational, not structural — newer units have lower R&M costs and more efficient manpower structures; corporate overheads are fully loaded into Gurgaon, making cross-cluster comparisons less meaningful.
• Operating leverage expected at Lucknow and Noida — management sees these units supporting margin stability or improvement as scale builds, though no explicit margin guidance was provided.
• No structural headwinds to margin expansion cited — management declined to give margin targets but noted only normal cost increases (increments, etc.) as ongoing factors.

Path to EBITDA Breakeven

• Noida total income Rs.855 Mn — up from Rs.525 Mn in Q4 FY 2025-2026, with EBITDA loss narrowing sharply to Rs.49 Mn from Rs.236 Mn in the prior quarter.
• Occupancy at 30-40% (misleading due to bed additions) — volumes are growing 30-40% QoQ; beds increased from 320 to 433 with new floors opened.
• All major specialties operational except liver transplant — high-end equipment (14 OTs, radiation oncology, robot, O-arm) already in place; no OT/ICU capex planned for the next couple of quarters.
• Management expects EBITDA breakeven earlier than previously expected — period unspecified, but the sharp loss reduction in Q1 FY 2026-2027 supports this trajectory.
• Cross-network coordination active — patient referrals and senior doctor movement (cardiac surgery, chest surgery) from Gurgaon to Noida help establish departments.

Capacity Growth & Capital Allocation

• Future capex of Rs.4,850 Cr for 2,950 beds — Rs.1,610 Mn was spent in Q1 FY 2026-2027; total announced pipeline represents nearly 3,350 additional beds (period unspecified for most).
• Guwahati hospital revised to 650 beds, project cost Rs.9,700 Mn — revised building norms doubled floor plate to ~60,000 sq ft, increased ORs from 13-14 to 28-30, and doubled cath labs/LINACs; no additional land cost.
• Gorakhpur scaled to 650-bed super specialty hospital — aimed at improving access for patients from the Northeast region; timeline is FY 2027-2028+.
• Near-term additions: 80 beds in Indore — coming on board by end of Q2/early Q3 FY 2026-2027; Gurgaon adding 44-45 ORs and 2-3 cath labs in Q2 FY 2026-2027.
• Government's tier 2/3 city policy — management noted the policy is "welcome but not needed for Medanta's Guwahati and Varanasi projects" as approvals are already in place and construction is commencing.

Doctors, Pharmacy & Specialties

• 70+ doctors onboarded in Q1 FY 2026-2027 — including over 50 senior clinicians across various specialties; senior clinical attrition negligible over the past 6-18 months.
• Lucknow performed 1,000+ robotic joint replacements — highlighting the ramp-up in high-complexity procedures at cluster 2 facilities.
• IPD volume growth: cluster 2 hospitals 27%, Lucknow/Patna 20%+ — mature Gurgaon facility grew 7-10%; management cited demand tailwinds from flight to quality care and rising health awareness across central and northern India.
• Oncology revenue share at 13.5% — down from 14.2% in Q1 FY 2025-2026 due to faster growth in other specialties (e.g., kidney/urology from 7.6% to 8.2%); cancer services overall are growing in absolute terms.
• Retail pharmacy: 13 stores outside hospitals — management plans steady expansion at 10 per quarter, potentially increasing to 15-20 over the next 2-3 years (FY 2027-2028 to FY 2028-2029), focused on UP and Bihar.
• International patient revenue Rs.782 Mn (+23% YoY) — OPD pharmacy revenue Rs.609 Mn (+51% YoY); the "CGHS rate hike announced in October 2025 was fully captured in Q1 FY 2026-2027" but did not move the needle as CGHS comprises only ~10-12% of revenue.
• Nursing and junior doctor attrition is industry-wide — management described "high attrition in nursing and junior doctors is industry-wide with no significant change" in recent periods.